Cytotoxic antibodies – valuable prognostic factor for long term kidney allograft survival
2010

Cytotoxic Antibodies and Kidney Transplant Survival

Sample size: 500 publication Evidence: moderate

Author Information

Author(s): Moise AM, Nedelcu D, Toader A, Sora M, Tica A, Ferastraoaru DE, Constantinescu I

Primary Institution: Carol Davila Medical University, Immunology of Transplantation, Fundeni–Centre for Immunogenetics and Virology, Bucharest, Romania

Hypothesis

Can cytotoxic antibodies predict long-term kidney allograft survival?

Conclusion

Patients post-kidney transplantation are at high risk of developing cytotoxic antibodies, especially if there is an HLA mismatch with the donor, which can predict acute graft rejection and graft failure.

Supporting Evidence

  • 29% of patients were sensitized before transplantation.
  • De novo antibodies were most common in the first 6 months post-transplant.
  • 86% of transplant recipients experienced at least one episode of acute rejection.

Takeaway

After getting a kidney transplant, some patients can develop harmful antibodies that might make their new kidney fail, especially if their body doesn't match the donor well.

Methodology

The study evaluated 500 Romanian patients on the kidney transplant waiting list, screening for anti-HLA class I and II antibodies using ELISA and Luminex methods.

Limitations

The study is limited to Romanian patients and may not be generalizable to other populations.

Participant Demographics

500 Romanian patients registered on the kidney transplant waiting list.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication